文献速递儿童青少年精神心境障碍

晨光疗法作为青少年中重度抑郁症住院治疗附加疗法的随机临床试验

Bright Light Therapy as Add-On to Inpatient Treatment in Youth With Moderate to Severe Depression: A Randomized Clinical Trial.
PubMed 文献 · JAMA Psychiatry · 2024-01-01

该双盲、安慰剂对照随机平行组试验在德国4所大学儿童青少年精神科住院部纳入227名12至18岁符合ICD-10重性抑郁障碍标准的患者,比较晨光疗法(10 000 lux)与安慰剂红光(100 lux)作为常规住院治疗附加疗法的疗效。意向性分析纳入224人,基线BDI-II均值为37.3,4周后平均降低7.5(95%CI -9.0至-6.0;Hedges g=0.71),但晨光疗法对BDI-II变化无显著影响(无显著组×时间效应)。结论不支持晨光疗法优于安慰剂红光疗法,两组均从常规治疗中同等获益。

要点

  • 晨光疗法(10 000 lux)作为住院常规治疗附加疗法,未显著优于安慰剂红光(100 lux)。
  • 意向性分析224人,4周后BDI-II平均降低7.5(95%CI -9.0至-6.0;Hedges g=0.71)。
  • 两组均显示相关症状减轻,但无显著组×时间效应。

核心结论

  • 在青少年中重度重性抑郁障碍住院患者中,晨光疗法未显示优于安慰剂红光疗法的疗效。
  • 两组均从常规住院治疗中同等获益,症状有相关减轻。

研究设计与样本

  • 双盲、安慰剂对照随机平行组试验,2018年3月至2020年11月入组,2021年5月完成随访。
  • 在德国4所大学儿童青少年精神科住院部开展,248名12至18岁符合ICD-10重性抑郁障碍标准的患者中227人被随机分组:晨光疗法组n=116,安慰剂红光组n=111。
  • 干预为最多20次晨光疗法(10 000 lux)或安慰剂红光(100 lux),附加于4周的多模式住院常规治疗。
  • 主要结局为意向性治疗样本中BDI-II评分从基线至治疗后的变化。

主要发现

  • 意向性分析纳入224人(192名女孩,32名男孩;平均[SD]年龄15.5[1.4]岁),基线BDI-II平均[SD]为37.3[8.7]。
  • 4周后BDI-II评分平均降低7.5(95%CI -9.0至-6.0;Hedges g=0.71)。
  • 晨光疗法对该变化无影响(无显著组×时间效应)。
  • 随访丢失率16周为31%(n=69),28周为49%(n=110)。
  • 整个试验期间发生10例严重不良事件,均被认为与研究治疗无关。

临床怎么用

  • 对于青少年中重度重性抑郁障碍住院患者,晨光疗法作为常规治疗附加疗法未显示额外获益,临床决策需结合其他证据。
  • 常规住院治疗本身可带来相关症状减轻,应继续保障其充分实施。

局限性

  • 随访丢失率较高:16周31%(n=69),28周49%(n=110)。
  • 研究仅纳入住院患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Major depressive disorder is one of the most common mental disorders among adolescents, entailing severe, long-term psychosocial impairment and a high risk of chronicity. In view of the large number of patients requiring treatment, along with insufficient treatment responses with small effect sizes, innovative adjunctive treatment strategies are urgently needed. OBJECTIVE: To investigate whether the effect of adolescent psychiatric inpatient treatment as usual for major depressive disorder can be enhanced by simultaneous use of morning bright light therapy. DESIGN, SETTING, AND PARTICIPANTS: This was a double-blind, placebo-controlled randomized parallel-group trial with enrollment between March 2018 and November 2020 and follow-up completed in May 2021. The study took place among inpatients at 4 university hospitals for child and adolescent psychiatry across Germany. Of 248 eligible youth aged 12 to 18 years fulfilling ICD-10 criteria for major depressive disorder, 227 were randomized to bright light therapy (n = 116) or placebo red light (n = 111); 151 participants completed the study. INTERVENTIONS: Up to 20 sessions of either morning bright light therapy with an intensity of 10 000 lux or placebo red light (100 lux) in addition to multimodal inpatient treatment as usual over 4 weeks. MAIN OUTCOMES AND MEASURES: The primary outcome was the change in Beck Depression Inventory-II (BDI-II) score from baseline to posttreatment in the intention-to-treat sample. RESULTS: Among the 224 patients included in the intention-to-treat analyses (192 girls and 32 boys; mean [SD] age, 15.5 [1.4] years), the mean (SD) BDI-II score at baseline was 37.3 (8.7). BDI-II scores were significantly reduced after 4 weeks (postassessment) by a mean of -7.5 (95% CI, -9.0 to -6.0; Hedges g = 0.71). Bright light therapy had no impact on this change (no significant group × time effect). Loss to follow-up was 31% (n = 69) at 16 weeks and 49% (n = 110) at 28 weeks. There were 10 serious adverse events throughout the whole trial, which were not considered related to study treatment. CONCLUSIONS AND RELEVANCE: The findings in this study did not indicate superiority of bright light therapy over placebo red light therapy in a large sample of adolescent inpatients with moderate or severe major depressive disorder. Both groups benefited equally from treatment as usual, showing relevant symptom reduction. TRIAL REGISTRATION: German Clinical Trials Register: DRKS00013188.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Legenbauer T, Kirschbaum-Lesch I, Jörke C, et al. Bright Light Therapy as Add-On to Inpatient Treatment in Youth With Moderate to Severe Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2024. PMID: 38477894. doi:10.1001/jamapsychiatry.2024.0103

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。